← Back to Explore

Investigating the Therapeutic Potential of Epigallocatechin Gallate and Theaflavin-3, 3'-digallate on Inhibiting ACE2-Spike Protein Binding and Mitigating Induced-Cellular Death by SARS-CoV-2

ISEF · 2022 Biochemistry Fourth Award

Overview

As of April 2022, there have been 500 million cases and 6.18 million deaths from COVID-19 worldwide. Current treatments are limited, thus necessitating the development of an effective therapeutic to combat infection and cell death. Epigallocatechin-gallate (EGCG) and Theaflavin-3,3’-digallate (TF3), catechins found in tea, have been recognized by biochemists for their antiviral properties. The COVID-19 spike protein binds to human angiotensin-converting enzyme-2 (ACE2) cell-surface receptors, thus making it a target for potential preventative treatments. The primary objectives of this study were to investigate the abilities of EGCG and TF3 to prevent spike receptor-binding-domain (RBD)-ACE2 binding and to improve metabolic activity in infected cells. Molecular docking identified binding affinities of ligands with the ACE2-receptor and spike-RBDs of COVID-19 variants. Cell survival, attachment, and caspase-3 assays were conducted with EGCG and TF3 to measure changes in cell viability and spike-RBD attachment in human U937 monocytic and SW1573 lung cells; both present ACE2-receptors on their surface. Results showed that EGCG and TF3 displayed the highest binding affinities amongst tested ligands to ACE2 and spike proteins. 50 µM EGCG and 5 µM TF3 significantly decreased cellular attachment mediated by the spike protein (p-value<.01), suggesting abilities to prevent infection. 5 µM EGCG/TF3 treatments increased cellular viability and decreased caspase-3 activity significantly, suggesting therapeutic effects in infected cells (p-value<.05). These results suggest EGCG and TF3 as preventative and curative therapeutics for the SARS-CoV-2 virus. Future clinical studies involving ingestion of these compounds should be conducted to determine viability of treatment in-vivo.

Awards (1)

  • Fourth Award of $500 $500

Competition history

  • ISEF 2022 Biochemistry · Entry BCHM026 · Atlanta, Georgia, United States

Resources

Related projects

Closest projects by meaning, across every fair and year in the corpus.

Source: Regeneron International Science and Engineering Fair

Save projects to your library

Sign in with Google to keep track of projects you find interesting, organized into folders. Browsing stays public.

Continue with Google